MedTrace Logo

Donafenib for Recurrent Cervical Cancer

NCT05310331 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-04

No results posted yet for this study

Summary

This study is to evaluate the safety and tolerability of Donafenib combined with paclitaxel and platinum ± programmed death 1 monoclonal antibody (PD-1 antibody) in patients with recurrent cervical cancer.

Conditions

  • Targeted Therapy
  • Chemotherapy
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Carcinoma
  • Persistent Advanced Cervical Carcinoma
  • Survival Outcomes
  • Adverse Effect

Interventions

COMBINATION_PRODUCT

Donafenib combined with paclitaxel and platinum ± PD-1 antibody

Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate \> 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min \< creatinine clearance rate \< 60ml/min) ± PD-1 antibody every 3 weeks.

Sponsors & Collaborators

  • Lei Li

    lead OTHER

Principal Investigators

  • Lei Li, M.D. · Peking Union Medical College Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-27
Primary Completion
2023-12-27
Completion
2024-06-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05310331 on ClinicalTrials.gov